Biomerica, Inc.
$2.18
▼
-0.91%
2026-04-21 05:43:01
www.biomerica.com
NCM: BMRA
Explore Biomerica, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$6.74 M
Current Price
$2.18
52W High / Low
$4.6 / $1.87
Stock P/E
—
Book Value
$1.5
Dividend Yield
—
ROCE
-122.16%
ROE
-84.3%
Face Value
—
EPS
$-2.51
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
53
Beta
0.2
Debt / Equity
6.4
Current Ratio
3.25
Quick Ratio
1.95
Forward P/E
5.46
Price / Sales
1.44
Enterprise Value
$4.17 M
EV / EBITDA
-0.81
EV / Revenue
0.94
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Beta Bionics, Inc. | $12.91 | — | $576.08 M | — | -24.07% | -40.26% | $32.71 / $8.8 | $6.48 |
| 2. | Avanos Medical, Inc. | $24.64 | — | $1.15 B | — | 1.7% | -9.07% | $24.72 / $9.3 | $16.75 |
| 3. | Enovis Corporation | $26.27 | — | $1.52 B | — | -0.58% | -58.27% | $37.85 / $21 | $26.05 |
| 4. | DexCom, Inc. | $63.4 | 30.77 | $24.57 B | — | 21.72% | 34.5% | $89.98 / $54.11 | $7.14 |
| 5. | Globus Medical, Inc. | $96.1 | 24.49 | $13.01 B | — | 11.18% | 12.29% | $101.4 / $51.79 | $33.86 |
| 6. | Zimmer Biomet Holdings, Inc. | $94.32 | 26.61 | $18.29 B | 1.04% | 6.61% | 5.6% | $108.29 / $84.59 | $64.95 |
| 7. | RxSight, Inc. | $7.44 | — | $314.04 M | — | -16.88% | -13.98% | $16.74 / $5.9 | $6.68 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.21 M | 1.38 M | 0.75 M | 1.12 M | 1.64 M | — |
| Operating Profit | -1.37 M | -1.12 M | -1.56 M | -1.21 M | -0.99 M | — |
| Net Profit | -1.32 M | 0 M | -1.54 M | -1.16 M | -0.95 M | — |
| EPS in Rs | -0.44 | 0 | -0.51 | -0.39 | -0.31 | -0.63 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 5.31 M | 5.42 M | 5.34 M | 18.87 M |
| Operating Profit | -5.14 M | -6.37 M | -7.22 M | -4.53 M |
| Net Profit | -4.97 M | -5.98 M | -7.14 M | -4.53 M |
| EPS in Rs | -1.65 | -1.98 | -2.36 | -1.5 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 5.95 M | 9.25 M | 14.45 M | 11.37 M |
| Total Liabilities | 1.84 M | 2.66 M | 2.73 M | 3.05 M |
| Equity | 4.11 M | 6.59 M | 11.72 M | 8.32 M |
| Current Assets | 4.88 M | 7.73 M | 12.8 M | 9.43 M |
| Current Liabilities | 1.74 M | 2.2 M | 1.95 M | 2.01 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -3.84 M | -5.36 M | -5.47 M | -0.48 M |
| Investing CF | -0.04 M | -0.12 M | -0.08 M | -0.17 M |
| Financing CF | 2.11 M | -0.08 M | 9.39 M | 2.39 M |
| Free CF | -3.88 M | -5.48 M | -5.55 M | -0.65 M |
| Capex | -0.04 M | -0.12 M | -0.08 M | -0.17 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 1.42% | -71.71% | — | — |
| Earnings Growth % | 16.27% | -57.58% | — | — |
| Profit Margin % | -110.4% | -133.73% | -24.01% | — |
| Operating Margin % | -117.58% | -135.29% | -24.03% | — |
| Gross Margin % | 11.28% | 8.35% | 15.78% | — |
| EBITDA Margin % | -110.67% | -128.71% | -20.87% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-04-21 | 1:0.125 |